A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 23, 2020

Primary Completion Date

July 23, 2024

Study Completion Date

July 31, 2026

Conditions

Muscular Dystrophy, Duchenne

Interventions

GENETIC

delandistrogene moxeparvovec

Single IV infusion of delandistrogene moxeparvovec

Trial Locations (5)

Washington University in St. Louis, St Louis

Children's Hospital of The King's Daughters, Norfolk

Nationwide Children's Hospital, Columbus

Stanford University, Palo Alto

University of California, Davis, Sacramento

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Sarepta Therapeutics, Inc.

INDUSTRY